Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.26 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized the importance of their clinical programs and ongoing research. However, they did not provide specific updates on financial performance.
Management did not provide specific revenue figures or guidance for future quarters.
The focus remains on ongoing clinical trials and product development.
Krystal Biotech's earnings report showed a loss per share of $0.26, with no revenue figures disclosed. The stock reacted negatively, declining by 1.94%. The lack of detailed financial guidance or revenue updates may have contributed to investor caution.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENBRIDGE INC
Nov 2, 2018